220 related articles for article (PubMed ID: 30976105)
1. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Fu P; Honda Y; Iyama K; Iwase H
Mod Pathol; 2013 Jan; 26(1):79-86. PubMed ID: 22918168
[TBL] [Abstract][Full Text] [Related]
3. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
8. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
9. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
12. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
13. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
Abubakar M; Guo C; Koka H; Zhu B; Deng J; Hu N; Zhou B; Garcia-Closas M; Lu N; Yang XR
Breast Cancer Res Treat; 2021 Sep; 189(2):483-495. PubMed ID: 34185195
[TBL] [Abstract][Full Text] [Related]
14. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
15. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
18. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
20. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
